

CRISPR Loss-of-Function Screen Identifies the Hippo Signalling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma

Shigeki Suemura, Takahiro Kodama, Yuta Myojin, Ryoko Yamada, Minoru Shigekawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi and Tetsuo Takehara




Figure S1. The distribution of gRNA abundance and tumour growth curve during CRISPR library screening. Twenty million HLF cells expressing Cas9 were transduced with the Brunello library at an MOI of 0.2. After 7 days of the selection of transduced cells by puromycin, 9.0×10^6 library-transduced cells were injected into the flanks of NOG mice and also stocked for subsequent gDNA isolation. Once each tumour volume reached 200 mm³, tumours were randomly divided into 2 groups and treated with either vehicle or 20 mg/kg regorafenib for 3 weeks. Then, all the tumours (3 tumours from the vehicle group and 3 tumours from the regorafenib group) were collected. Genomic DNA from transduced cells and xenografted tumours was extracted. gRNA sequences integrated into the gDNA were PCR amplified and sequenced in Illumina HiSeq. **(A)** Log2 normalized read counts of each gRNA were plotted to determine the distribution of gRNA abundance inside cells and tumours **(B)** Tumour volumes were measured every 4 days after treatment initiation.






Figure S2. Correlation between YAP activation and regorafenib resistance. Correlation between the IC₅₀ values of regorafenib and CYR61 mRNA levels against 12 human liver cancer cell lines. The Pearson correlation coefficient is shown as the *r* value.

(A)



(B)



(C)




Figure S3. Genetic suppression of YAP or Bcl-xL restores regorafenib sensitivity in HCC cells. (A) Three days after transfection with the NC or YAP siRNA, cells were treated with DMSO or 15 μ M regorafenib for 48 hours. Cell viability was measured by WST-1 assays in HLF ($N = 4$ for each and *, † $p < 0.05$ vs all). (B,C) Three days after transfection with the NC or Bcl-xL siRNA, cells were treated with DMSO or 15 μ M regorafenib for 48 hours. Cell viability was measured by WST-1 assays (B) and apoptosis was assessed by the caspase-3/7 activity of the culture supernatant (C) in HLF ($N = 4$ for each and *, † $p < 0.05$ vs all).

Figure 1A




Figure 3C




Figure 4A




Figure 4A Hep3B





Figure 4A Huh-7







Figure 4F




Figure 4G




Figure 4H




Figure S4. Original images of western blot with molecular weight markers.



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).